Blake Borgeson - 13 Dec 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
13 Dec 2022
Net transactions value
-$79,598
Form type
4
Filing time
15 Dec 2022, 16:26:25 UTC
Previous filing
01 Dec 2022
Next filing
29 Dec 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale $79,598 -8,885 -0.12% $8.96 7,637,157 13 Dec 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.78 to $9.53 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.